MoneyWorks4Me

Indoco Remedies informs about outcome of board meeting

24 Jan 2023 Evaluate
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), Indoco Remedies has informed that the Board of Directors of the Company at its Meeting held today i.e. 24th January, 2023 has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with the Limited Review Report issued by the Statutory Auditor of the Company.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..